Registration No. 333-237820
(To prospectus dated May 14, 2020)
Pre-funded warrants to purchase shares of common stock
| | Per share | | | Per pre-funded warrant | | | Total | |
Public offering price | | | $ | | | $ | | | $ |
Underwriting discounts and commissions(1) | | | $ | | | $ | | | $ |
Proceeds to BioCryst, before expenses | | | $ | | | $ | | | $ |
(1) | We have agreed to reimburse the underwriters for certain FINRA-related expenses. See “Underwriting.” |
J.P. Morgan | | | Piper Sandler |